Human Rabies Immunoglobulin Market

Rabies immunoglobulin (RIG) is a medication made up of antibodies against the rabies virus. It is used to prevent rabies following exposure.

Figure Human Rabies Immunoglobulin (IM) is rabies immunoglobulin antibody by the high price of healthy human plasma protein low temperature ethanol separation or other separation methods approved separation and purification, and by virus removal and inactivation treatment is made. Mainly used for rabies or other crazy animal bites, scratches patient's passive immunization.

In Human Rabies Immunoglobulin Market , we study ERIG (Equine Rabies Immunoglobulin) and HRIG (Human Rabies Immunoglobulin)
Human Rabies Immunoglobulin Market contains market size and forecasts of Human Rabies Immunoglobulin (IM) in global, including the following market information:
Global Human Rabies Immunoglobulin (IM) Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Human Rabies Immunoglobulin (IM) Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Human Rabies Immunoglobulin (IM) companies in 2021 (%)
The global Human Rabies Immunoglobulin (IM) market was valued at 407.5 million in 2021 and is projected to reach US$ 610 million by 2028, at a CAGR of 5.9% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
ERIG Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Human Rabies Immunoglobulin (IM) include CSL Behring, Grifols, Sanofi, Sichuan Yuanda Shuyang, CNBG, Kamada, CBPO, Shuanglin Bio and Weiguang Bio, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Human Rabies Immunoglobulin (IM) manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Human Rabies Immunoglobulin (IM) Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Human Rabies Immunoglobulin (IM) Market Segment Percentages, by Type, 2021 (%)
ERIG
HRIG
Global Human Rabies Immunoglobulin (IM) Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Human Rabies Immunoglobulin (IM) Market Segment Percentages, by Application, 2021 (%)
Category II Exposure
Category III Exposure
Global Human Rabies Immunoglobulin (IM) Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Human Rabies Immunoglobulin (IM) Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Human Rabies Immunoglobulin (IM) revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Human Rabies Immunoglobulin (IM) revenues share in global market, 2021 (%)
Key companies Human Rabies Immunoglobulin (IM) sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Human Rabies Immunoglobulin (IM) sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
CSL Behring
Grifols
Sanofi
Sichuan Yuanda Shuyang
CNBG
Kamada
CBPO
Shuanglin Bio
Weiguang Bio
Shanghai RAAS
Bharat Serum
VINS